Logo

Biocrates To Provide Metabolomics Services for EU Cancer Biomarker Study

May 10, 2007
NEW YORK (GenomeWeb News) - Biocrates Life Sciences has joined a European Union project to find diagnostic biomarkers for colon and breast cancer, the company said today.
 
Biocrates, based in Innsbruck, Austria, said that it will perform metabolomics services for the study, called COBRED for Colon and Breast cancer Diagnostics.
 
The company said it will use its TargetIDQ metabolomics platform to identify and quantify more than 1,000 metabolites in the study.
 
The study is funded by the EU’s Sixth Framework program and involves eight partners from France, Hungary, Estonia, and Austria. The goal of the study is to discover biomarkers to assess the risk of cancer recurrence after initial tumor removal.

Breaking News
The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.